-transparent.png){kind=logo}
[Atrial fibrillation : new anticoagulants and antiarrhythmic drugs]. 2012
Abteilung für Rhythmologie, Department für Kardiologie und Angiologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, Münster, Germany. elif.kaya@ukmuenster.de
Atrial fibrillation is the most common form of arrhythmia and one of the most frequent causes of ischemic stroke. Several new anticoagulants have recently been introduced as alternatives to vitamin-K antagonists for prophylaxis of ischemic stroke and tested in phase-3 studies for efficacy and safety. Identifying patients who will profit in particular from the new anticoagulant therapy is crucial to the clinical application of these drugs. Vernakalant and dronedarone are new antiarrhythmic drugs for rhythm control of atrial fibrillation. However, therapeutic efficacy of the new agents still has to be proven.
Related Publications
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
December 2009,
Annales de cardiologie et d'angeiologie,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
November 2007,
American heart journal,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
November 2011,
Stroke,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
April 2010,
Lancet (London, England),
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
January 2010,
Duodecim; laaketieteellinen aikakauskirja,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
January 2005,
Progress in cardiovascular diseases,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
December 2002,
La Revue du praticien,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
June 2011,
Expert opinion on pharmacotherapy,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
June 2002,
La Revue du praticien,
E Kaya, and
G Frommeyer, and
G Mönnig, and
L Eckardt
December 2008,
Herz,
